Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA901 plus sunitinib versus sunitinib alone in first-line advanced/metastatic clear-cell renal cell carcinoma
2010-022459-45Phase 3Completed
- Sponsor
- Immatics
- Start
- Oct 2010
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of IMA901 in renal cell carcinoma (RCC) (2 arms), sponsored by Immatics. Primary endpoint: Overall survival. Started Oct 2010; status: completed.
02
Drugs
IMA901
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2010-022459-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022459-45.